Table 1 Patient Demographic and Clinical Characteristics
From: Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy
Cohort (%) | JIA (%) | Other Associated Systemic Disease(%) | Idiopathic (%) | |
|---|---|---|---|---|
No. of Patients | 166 | 91 (54.8) | 9 (5.4) | 66 (39.8) |
Female | 99 (59.6) | 62 (68.1) | 2 (22.2) | 35 (53) |
Age at diagnosis | ||||
Average | 8.03y | 5.9y | 10.5y | 10.7y |
Median | 7y | 5y | 12y | 11y |
Referral type | ||||
Tertiary | 93 (56) | 56 (61.5) | 6 (66.7) | 31 (47) |
Ethnicity | ||||
Caucasian | 128 (77.1) | 73(80.2) | 6 (66.7) | 49 (74.2) |
Asian | 8 (4.8) | 2 (2.2) | 2 (22.2) | 4 (6) |
African | 1 (0.6) | 0 | 0 | 1 (1.5) |
Other | 7 (4.2) | 2 (2.2) | 1 (11.1) | 4 (6) |
Unknown | 22 (13.3) | 14 (15.4) | 0 | 8 (12.1) |
Laterality on presentation | ||||
Bilateral | 116 (69.9) | 62 (68.1) | 5 (55.6) | 49 (74.2) |
Anatomic Localisation | ||||
Anterior | 125 (75.3) | 89 (97.8) | 5 (55.6) | 31 (47) |
Intermediate | 29 (17.5) | 0 | 1 (11.1) | 28 (42.4) |
Posterior | 1 (0.6) | 0 | 0 | 1 (1.5) |
Panuveitis | 11 (6.6) | 2 (2.2) | 3 (33.3) | 6 (9.1) |
Visual Impairment at baseline (per eye) | ||||
> 0.3logMAR | 43 (18.4) | 22 (18.6) | 3 (27.3) | 18 (17.1) |
≥ 1.0 logMAR | 10 (4.3) | 7 (5.9) | 0 | 3 (2.9) |
Medication use over study | ||||
Corticosteroids | ||||
Topical CS | 155 (93.4) | 91 (100) | 8 (88.9) | 56 (84.8) |
Systemic CS | 58 (34.9) | 28 (30.8) | 7 (77.8) | 23 (34.8) |
Peri/Intraocular | 12 (7.2) | 6 (6.6) | 3 (33.3) | 6 (9.1) |
Steroids | ||||
Conventional DMARD | 121 (72.9) | 82 (90.1) | 6 (66.7) | 33 (50) |
Methotrexate | 121 (72.9) | 82 (90.1) | 6 (66.7) | 33 (50) |
Only Methotrexate | 47 (28.3%) | 35 (38.5) | 1 (11.1) | 11 (16.7) |
Mycophenolate | 36 (21.7) | 19 (20.9) | 2 (22.2) | 15 (22.7) |
mofetil | ||||
Tacrolimus | 6 (3.6) | 3 (3.3) | 0 | 3 (4.5) |
Ciclosporin | 3 (1.8) | 2 (2.2) | 0 | 1 (1.5) |
Biologics | 58 (34.9) | 43 (47.3) | 5 (55.6) | 10 (15.2) |
Adalimumab | 52 (31.3) | 38 (41.8) | 5 (55.6) | 9 (13.6) |
Infliximab | 19 (11.4) | 14 (15.4) | 4 (44.4) | 1 (1.5) |
Abatacept | 3 (1.8) | 3 (1.8) | 0 | 0 |
Tocilizumab | 2 (1.2) | 2 (1.2) | 0 | 0 |